According to Mehr news agency, citing New Atlas, this is probably the first genetic silencing method approved on the market for such a purpose, which replaces long-term drug use and reduces the risk of heart diseases.
Researchers hope that Scribe Therapeutics’ STX-1150 treatment, which epigenetically turns off the PCSK9 gene in the liver, will reduce low-density lipoprotein cholesterol (LDL-C). Of course, this is not the first time that news about the invention of such a treatment method has been published.
STX-1150 treatment targets hypercholesterolemia, which is considered a key factor in atherosclerotic cardiovascular disease (ASCVD). This method epigenetically turns off the PCSK9 gene to lower LDL-C without any permanent changes in DNA.
Benjamin Oaks, Chief Executive Officer of Scribe, says: We designed STX-1150 to overcome many of the limitations of current fat loss treatments. This treatment is based on a powerful method of epigenetic silencing and significantly reduces the risk of heart disease management for millions of patients.
Instead of interrupting or permanently changing the DNA, the said treatment basically creates modifications and methylation marks at the PCSK9 site in liver cells and shuts down the gene expression in such a way that it can be reversed if needed.
Latest Passing over countries : Spain | Dominica | United Arab Emirates
RCO NEWS
